Jennison Associates
VKTX icon

Jennison Associates’s Viking Therapeutics VKTX Stock Holding History

Jennison Associates’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-8,268
Closed -$438K – 647
2024
Q2 		$438K Buy
8,268
+978
+13% +$64.1K ﹤0.01% 554
2024
Q1 		$598K Buy
+7,290
New +$324K ﹤0.01% 550
2019
Q4 		– Sell
-463,948
Closed -$3.19M – 673
2019
Q3 		$3.19M Sell
463,948
-43,631
-9% -$324K ﹤0.01% 479
2019
Q2 		$4.21M Sell
507,579
-5,116
-1% -$43.7K ﹤0.01% 482
2019
Q1 		$5.1M Sell
512,695
-108,094
-17% -$905K 0.01% 468
2018
Q4 		$4.75M Buy
620,789
+75,389
+14% +$901K 0.01% 485
2018
Q3 		$9.5M Buy
+545,400
New +$6.49M 0.01% 474

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Jennison Associates's VKTX Position: Q3 2024 in Review

Jennison Associates sold out of Viking Therapeutics (VKTX) in Q3 2024, closing a stake of 8,268 shares — an estimated $438K sold.

Jennison Associates first reported a position in VKTX in Q3 2018 and held it in 7 quarters. The position peaked at $9.5M in Q3 2018. 422 funds tracked by Wall St. Rank hold VKTX as of Q3 2024.

  • Jennison Associates reported no remaining Viking Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Jennison Associates sold 8,268 Viking Therapeutics shares in Q3 2024, an estimated $438K.
  • Jennison Associates first reported a position in Viking Therapeutics in Q3 2018 and held it in 7 quarters.
  • Jennison Associates's Viking Therapeutics position peaked at $9.5M in Q3 2018.
  • 422 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2024.

Based on Jennison Associates's 13F filing for Q3 2024, filed 8 Nov 2024.